|
1
|
Nakayama H and Takayama T: Role of
surgical resection for hepatocellular carcinoma based on Japanese
clinical guidelines for hepatocellular carcinoma. World J Hepatol.
7:261–269. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Braillon A: Hepatocellular carcinoma.
Lancet. 380:469–471. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Knudson AG Jr: Mutation and cancer:
Statistical study of retinoblastoma. Proc Natl Acad Sci USA.
68:820–823. 1971.PubMed/NCBI View Article : Google Scholar
|
|
5
|
He X, Yan YL, Eberhart JK, Herpin A,
Wagner TU, Schartl M and Postlethwait JH: miR-196 regulates axial
patterning and pectoral appendage initiation. Dev Biol.
357:463–477. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Poy MN, Hausser J, Trajkovski M, Braun M,
Collins S, Rorsman P, Zavolan M and Stoffel M: miR-375 maintains
normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci
USA. 106:5813–5818. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM,
Sung CO, Baek D, Haq F, Ansari AA, Lee SY, et al: Genomic portrait
of resectable hepatocellular carcinomas: Implications of RB1 and
FGF19 aberrations for patient stratification. Hepatology.
60:1972–1982. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takai A, Dang HT and Wang XW:
Identification of drivers from cancer genome diversity in
hepatocellular carcinoma. Int J Mol Sci. 15:11142–11160.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hu TH, Huang CC, Lin PR, Chang HW, Ger LP,
Lin YW, Changchien CS, Lee CM and Tai MH: Expression and prognostic
role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular
carcinoma. Cancer. 97:1929–1940. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kawamura N, Nagai H, Bando K, Koyama M,
Matsumoto S, Tajiri T, Onda M, Fujimoto J, Ueki T, Konishi N, et
al: PTEN/MMAC1 mutations in hepatocellular carcinomas: Somatic
inactivation of both alleles in tumors. Jpn J Cancer Res.
90:413–418. 1999.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hellebrekers DM, Griffioen AW and van
Engeland M: Dual targeting of epigenetic therapy in cancer. Biochim
Biophys Acta. 1775:76–91. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nault JC and Villanueva A: Intratumor
molecular and phenotypic diversity in hepatocellular carcinoma.
Clin Cancer Res. 21:1786–1788. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nault JC, Mallet M, Pilati C, Calderaro J,
Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and
Zucman-Rossi J: High frequency of telomerase reverse-transcriptase
promoter somatic mutations in hepatocellular carcinoma and
preneoplastic lesions. Nat Commun. 4(2218)2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Vishnoi A and Rani S: MiRNA biogenesis and
regulation of diseases: An overview. Methods Mol Biol. 1509:1–10.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993.PubMed/NCBI View Article : Google Scholar
|
|
16
|
van Rooij E and Olson EN: MicroRNAs:
Powerful new regulators of heart disease and provocative
therapeutic targets. J Clin Invest. 117:2369–2376. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Johnston RJ Jr, Chang S, Etchberger JF,
Ortiz CO and Hobert O: MicroRNAs acting in a double-negative
feedback loop to control a neuronal cell fate decision. Proc Natl
Acad Sci USA. 102:12449–12454. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kloosterman WP, Wienholds E, de Bruijn E,
Kauppinen S and Plasterk RH: In situ detection of miRNAs in animal
embryos using LNA-modified oligonucleotide probes. Nat Methods.
3:27–29. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Appolloni R, Formicola R, Scurci M,
Appolloni R and Colonna GB: Lupus anticoagulant and bilateral optic
disc edema: A case report. Ann Ophthalmol. 23:312–317.
1991.PubMed/NCBI
|
|
21
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hammond SM: MicroRNAs as tumor
suppressors. Nat Genet. 39:582–583. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Finnerty JR, Wang WX, Hébert SS, Wilfred
BR, Mao G and Nelson PT: The miR-15/107 group of microRNA genes:
Evolutionary biology, cellular functions, and roles in human
diseases. J Mol Biol. 402:491–509. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liu Q, Li Y, Lv W, Zhang G, Tian X, Li X,
Cheng H and Zhu C: UCA1 promotes cell proliferation and invasion
and inhibits apoptosis through regulation of the miR129-SOX4
pathway in renal cell carcinoma. Onco Targets Ther. 11:2475–2487.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Xu S, Yi XM, Zhang ZY, Ge JP and Zhou WQ:
miR-129 predicts prognosis and inhibits cell growth in human
prostate carcinoma. Mol Med Rep. 14:5025–5032. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fu S, Fei Q, Jiang H, Chuai S, Shi S,
Xiong W, Jiang L, Lu C, Atadja P, Li E and Shou J: Involvement of
histone acetylation of Sox17 and Foxa2 promoters during mouse
definitive endoderm differentiation revealed by microRNA profiling.
PLoS One. 6(e27965)2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ,
Zhou H and Qu LH: Liver-enriched transcription factors regulate
microRNA-122 that targets CUTL1 during liver development.
Hepatology. 52:1431–1442. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Huang S and He X: The role of microRNAs in
liver cancer progression. Br J Cancer. 104:235–240. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang Y, Yang P and Wang XF:
Microenvironmental regulation of cancer metastasis by miRNAs.
Trends Cell Biol. 24:153–160. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chai ZT, Kong J, Zhu XD, Zhang YY, Lu L,
Zhou JM, Wang LR, Zhang KZ, Zhang QB, Ao JY, et al: MicroRNA-26a
inhibits angiogenesis by down-regulating VEGFA through the
PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma. PLoS One.
8(e77957)2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Laudadio I, Manfroid I, Achouri Y, Schmidt
D, Wilson MD, Cordi S, Thorrez L, Knoops L, Jacquemin P, Schuit F,
et al: A feedback loop between the liver-enriched transcription
factor network and miR-122 controls hepatocyte differentiation.
Gastroenterology. 142:119–129. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato
JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A
expression in hepatocellular carcinoma. J Clin Invest. 123:285–298.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Wang X, Li J, Xu X, Zheng J and Li Q:
miR-129 inhibits tumor growth and potentiates chemosensitivity of
neuroblastoma by targeting MYO10. Biomed Pharmacother.
103:1312–1318. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ramachandran S, Lowenthal A, Ritner C,
Lowenthal S and Bernstein HS: Plasma microvesicle analysis
identifies microRNA 129-5p as a biomarker of heart failure in
univentricular heart disease. PLoS One. 12(e0183624)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lv G, Hu Z, Tie Y, Du J, Fu H, Gao X and
Zheng X: MicroRNA-451 regulates activating transcription factor 2
expression and inhibits liver cancer cell migration. Oncol Rep.
32:1021–1028. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Carragee EJ, Hurwitz EL and Weiner BK: A
critical review of recombinant human bone morphogenetic protein-2
trials in spinal surgery: Emerging safety concerns and lessons
learned. Spine J. 11:471–491. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jiramongkolchai P, Owens P and Hong CC:
Emerging roles of the bone morphogenetic protein pathway in cancer:
Potential therapeutic target for kinase inhibition. Biochem Soc
Trans. 44:1117–1134. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sampath TK, Coughlin JE, Whetstone RM,
Banach D, Corbett C, Ridge RJ, Ozkaynak E, Oppermann H and Rueger
DC: Bovine osteogenic protein is composed of dimers of OP-1 and
BMP-2A, two members of the transforming growth factor-beta
superfamily. J Biol Chem. 265:13198–13205. 1990.PubMed/NCBI
|
|
42
|
Katsuno Y, Hanyu A, Kanda H, Ishikawa Y,
Akiyama F, Iwase T, Ogata E, Ehata S, Miyazono K and Imamura T:
Bone morphogenetic protein signaling enhances invasion and bone
metastasis of breast cancer cells through Smad pathway. Oncogene.
27:6322–6333. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Arnold SF, Tims E and Mcgrath BE:
Identification of bone morphogenetic proteins and their receptors
in human breast cancer cell lines: Importance of BMP2. Cytokine.
11:1031–1037. 1999.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Davies SR, Watkins G, Douglas-Jones A,
Mansel RE and Jiang WG: Bone morphogenetic proteins 1 to 7 in human
breast cancer, expression pattern and clinical/prognostic
relevance. J Exp Ther Oncol. 7:327–338. 2008.PubMed/NCBI
|
|
45
|
Budhu A, Forgues M, Ye QH, Jia HL, He P,
Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW:
Prediction of venous metastases, recurrence, and prognosis in
hepatocellular carcinoma based on a unique immune response
signature of the liver microenvironment. Cancer Cell. 10:99–111.
2006.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Aravalli RN, Cressman EN and Steer CJ:
Cellular and molecular mechanisms of hepatocellular carcinoma: An
update. Arch Toxicol. 87:227–247. 2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
van Zijl F, Zulehner G, Petz M, Schneller
D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H and Mikulits
W: Epithelial-mesenchymal transition in hepatocellular carcinoma.
Future Oncol. 5:1169–1179. 2009.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Belghiti J and Fuks D: Liver resection and
transplantation in hepatocellular carcinoma. Liver Cancer. 1:71–82.
2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zou CD, Zhao WM, Wang XN, Li Q, Huang H,
Cheng WP, Jin JF, Zhang H, Wu MJ, Tai S, et al: MicroRNA-107: A
novel promoter of tumor progression that targets the CPEB3/EGFR
axis in human hepatocellular carcinoma. Oncotarget. 7:266–278.
2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lv G, Wu M, Wang M, Jiang X, Du J, Zhang
K, Li D, Ma N, Peng Y, Wang L, et al: miR-320a regulates high
mobility group box 1 expression and inhibits invasion and
metastasis in hepatocellular carcinoma. Liver Int. 37:1354–1364.
2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ahmed NM, Youns M, Soltan MK and Said AM:
Design, synthesis, molecular modelling, and biological evaluation
of novel substituted pyrimidine derivatives as potential anticancer
agents for hepatocellular carcinoma. J Enzyme Inhib Med Chem.
34:1110–1120. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Su CM, Hou GG, Wang CH, Zhang HQ, Yang C,
Liu M and Hou Y: Potential multifunctional agents with
anti-hepatoma and anti-inflammation properties by inhibiting NF-κB
activation. J Enzyme Inhib Med Chem. 34:1287–1297. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zhao J, Wang Y, Han M, Lu H, Chen X, Liu
S, Yuan X, Han K, Liang P and Cheng J: P7TP3 inhibits tumor
development, migration, invasion and adhesion of liver cancer
through the Wnt/β-catenin signaling pathway. Cancer Sci.
111:994–1007. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Xia Y, Zhong J, Zhao M, Tang Y, Han N, Hua
L, Xu T, Wang C and Zhu B: Galactose-modified selenium
nanoparticles for targeted delivery of doxorubicin to
hepatocellular carcinoma. Drug Deliv. 26:1–11. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Aden DP, Fogel A, Plotkin S, Damjanov I
and Knowles BB: Controlled synthesis of HBsAg in a differentiated
human liver carcinoma-derived cell line. Nature. 282:615–616.
1979.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Knowles BB, Howe CC and Aden DP: Human
hepatocellular carcinoma cell lines secrete the major plasma
proteins and hepatitis B surface antigen. Science. 209:497–499.
1980.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Vasuri F, Visani M, Acquaviva G, Brand T,
Fiorentino M, Pession A, Tallini G, D'Errico A and de Biase D: Role
of microRNAs in the main molecular pathways of hepatocellular
carcinoma. World J Gastroenterol. 24:2647–2660. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Mukai T, Otsuka F, Otani H, Yamashita M,
Takasugi K, Inagaki K, Yamamura M and Makino H: TNF-alpha inhibits
BMP-induced osteoblast differentiation through activating SAPK/JNK
signaling. Biochem Biophys Res Commun. 356:1004–1010.
2007.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Huang RL, Yuan Y, Tu J, Zou GM and Li Q:
Opposing TNF-α/IL-1β- and BMP-2-activated MAPK signaling pathways
converge on Runx2 to regulate BMP-2-induced osteoblastic
differentiation. Cell Death Dis. 5(e1187)2014.PubMed/NCBI View Article : Google Scholar
|
